AZD5718

DRUG5 trials

Sponsors

AstraZeneca, National University Heart Centre, Singapore

Conditions

Acute Coronary SyndromeCardiovascular DiseaseChronic Kidney DiseaseCoronary Artery Disease

Phase 1

A Study to Assess the Effect of Multiple Doses of AZD5718 on Pharmacokinetics of Oral Midazolam in Healthy Subjects

CompletedNCT04492709

AstraZenecaCardiovascular Disease

Start: 2020-07-30End: 2020-10-19Updated: 2020-11-03

Study to Assess Relative Bioavailability and Safety of AZD5718 in Healthy Volunteers

CompletedNCT04734275

AstraZenecaChronic Kidney Disease

Start: 2021-02-01End: 2021-03-25Updated: 2021-12-06

Phase 2

AZD5718 Phase IIa Study to Evaluate Efficacy, Safety and Tolerability of Oral AZD5718 in Patients With Coronary Artery Disease (CAD).

CompletedNCT03317002

AstraZenecaCoronary Artery Disease

Start: 2017-10-30End: 2020-04-08Updated: 2021-06-30

A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease

TerminatedNCT04492722

AstraZenecaChronic Kidney Disease

Start: 2020-10-01End: 2022-09-06Updated: 2024-12-20

PASSIvation of Vulnerable Plaque With AZD5718 in AcuTe Coronary syndromE

TerminatedNCT04601467

National University Heart Centre, SingaporeAcute Coronary Syndrome

Start: 2021-07-12End: 2024-08-14Updated: 2025-04-27

Related Papers

Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study

International Journal of Cardiology2022-07-139 citations

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD.

2021-08-279 citations

Phase 1 Pharmacokinetic Study of AZD5718 in Healthy Volunteers: Effects of Coadministration With Rosuvastatin, Formulation and Food on Oral Bioavailability

Clinical Pharmacology in Drug Development2019-12-0220 citations